Athira’s alternative Alzheimer’s approach runs into a PhII brick wall

Athira Pharma reported another setback Wednesday as its mid-stage Alzheimer’s study failed, becoming the latest biotech to come up short in the disease. The Seattle-area company said the Phase II trial comparing its lead candidate fosgonimeton, formerly ATH-1017, against placebo did not achieve its primary endpoint nor a litany of…

Click here to view original post